XML 261 R215.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment information - Schedule of Segment Results (Details) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 EUR (€) segment | Dec. 31, 2022 EUR (€) segment | Dec. 31, 2021 EUR (€)
Disclosure of operating segments [line items] |  |  |
Net sales | € 43,070 | € 42,997 | € 37,761
Other revenues | 3,374 | 2,392 | 1,414
Cost of sales | (14,236) | (13,695) | (12,255)
Research and development expenses | (6,728) | (6,706) | (5,692)
Selling and general expenses | (10,692) | (10,492) | (9,555)
Share of profit/(loss) from investments accounted for using the equity method | (115) | 68 | 39
Net income attributable to non-controlling interests | € 36 | € 113 | 56
Number of operating segments | segment | 2 | 3 |
Total Sanofi |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales | € 43,070 | € 42,997 | 37,761
Other revenues | 3,374 | 2,392 | 1,414
Cost of sales | (14,216) | (13,692) | (12,251)
Research and development expenses | (6,728) | (6,706) | (5,692)
Selling and general expenses | (10,692) | (10,492) | (9,555)
Other operating income and expenses | (2,224) | (1,514) | (946)
Share of profit/(loss) from investments accounted for using the equity method | 122 | 88 | 39
Net income attributable to non-controlling interests | (36) | (33) | (56)
Business operating income | 12,670 | 13,040 | 10,714
Biopharma |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales | 37,890 | 37,812 | 33,293
Other revenues | 3,322 | 2,330 |
Cost of sales | (12,282) | (11,793) |
Research and development expenses | (6,509) | (6,503) |
Selling and general expenses | (8,868) | (8,736) |
Other operating income and expenses | (2,387) | (1,679) |
Share of profit/(loss) from investments accounted for using the equity method | 101 | 76 |
Net income attributable to non-controlling interests | (20) | (17) |
Business operating income | 11,247 | 11,490 |
Pharmaceuticals |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales |  |  | 26,970
Other revenues |  |  | 264
Cost of sales |  |  | (6,965)
Research and development expenses |  |  | (4,330)
Selling and general expenses |  |  | (5,326)
Other operating income and expenses |  |  | (1,172)
Share of profit/(loss) from investments accounted for using the equity method |  |  | 17
Net income attributable to non-controlling interests |  |  | (49)
Business operating income |  |  | 9,409
Vaccines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales |  |  | 6,323
Other revenues |  |  | 1,095
Cost of sales |  |  | (3,430)
Research and development expenses |  |  | (712)
Selling and general expenses |  |  | (805)
Other operating income and expenses |  |  | 128
Share of profit/(loss) from investments accounted for using the equity method |  |  | 11
Net income attributable to non-controlling interests |  |  | (1)
Business operating income |  |  | 2,609
Consumer Healthcare |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales | 5,180 | 5,185 | 4,468
Other revenues | 52 | 62 | 55
Cost of sales | (1,933) | (1,903) | (1,606)
Research and development expenses | (219) | (205) | (153)
Selling and general expenses | (1,828) | (1,761) | (1,388)
Other operating income and expenses | 181 | 148 | 111
Share of profit/(loss) from investments accounted for using the equity method | 21 | 12 | 11
Net income attributable to non-controlling interests | (16) | (16) | (5)
Business operating income | 1,438 | 1,522 | 1,493
Other |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales | 0 | 0 | 0
Other revenues | 0 | 0 | 0
Cost of sales | (1) | 4 | (250)
Research and development expenses | 0 | 2 | (497)
Selling and general expenses | 4 | 5 | (2,036)
Other operating income and expenses | (18) | 17 | (13)
Share of profit/(loss) from investments accounted for using the equity method | 0 | 0 | 0
Net income attributable to non-controlling interests | 0 | 0 | (1)
Business operating income | € (15) | € 28 | € (2,797)

X
- Definition The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 99 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_CostOfSales
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherRevenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph 12 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 81B -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProfitLossAttributableToNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 126 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense relating to selling, general and administrative activities of the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 28 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -Subparagraph g -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 82 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business operating income. + References No definition available. + Details
Name: | sny_BusinessOperatingIncome
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of operating segments. + References No definition available. + Details
Name: | sny_NumberOfOperatingSegments1
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |